| 摘要: |
| 目的 分析miR-212在乳腺浸润性导管癌组织中的表达及与乳腺癌临床病理特征之间的相关性，并分析其效应。
方法 采用茎环RT-qPCR 方法检测38例乳腺癌及癌旁正常乳腺组织标本中miR-212的表达，统计分析其表达水平与乳腺癌常用临床病理指标间的关系。不同浓度miR-212 inhibitor转染MCF7乳腺癌细胞，通过MTT 法分析细胞活性，通过Tran-swell实验检测细胞的侵袭能力。结果 与癌旁正常乳腺组织比较，乳腺癌组织中miR-212 的表达明显升高（P＜0.05）；分析miR-212 表达水平与乳腺癌常用临床病理指标间的关系发现，miR-212 表达水平与乳腺癌细胞与淋巴结转移、TNM分期相关及增殖指数（ki67）相关（P＜0.05），与月经状况、肿块大小、雌激素和孕激素受体状态、Her-2表达未见显著相关性（P ＞0.05）。细胞干预实验显示，与空白对照组、阴性对照组比较，miR-212 inhibitor可明显抑制MCF7细胞增殖活性（P＜0.05）和细胞迁移（P＜0. 01）。结论 乳腺癌组织高表达的miR-212
在乳腺癌发展过程中发挥重要作用，有望成为乳腺癌防治的一个新靶点。 |
| 关键词: 微小RNA miR-212 乳腺癌 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Analysis of the expression and effect in invasive ductal carcinoma of the breast miR-212 |
|
QU Haijiang,ZHANG Xiaohua,HUANG Guanli,HU Zhe,WEI Zhiping
|
|
the First Affiliated Hospital of Wenzhou Medical University
|
| Abstract: |
| Objective To investigate the expression of miR-212 in breast invasive ductal carcinoma and its correlation with clinicopathological characteristics of the cancer. Methods The expression of miR-212 was detected by loop RT-qPCR in cancer and pericancerous tissue specimens of 38 breast cancer patients. The relationship between miR-212 expression l and clinicopathological characteristics was analyzed. MiR-212 inhibitor was transfected into human breast cancer MCF7 cells, then cell proliferation was determined by MTT method and cell invasive ability was measured by Tran-swell assay. Results Compared pericancerous breast tissues, the expression of miR-212 in cancer tissues was significantly higher (P＜0.05); the expression level of miR-212 was correlated with lymph node metastasis, TNM staging and proliferation index (Ki67) (P＜0.05), not correlated with menopausal status, tumor size, estrogen and progesterone receptor status, and Her-2 status (P＞0.05). Compared
with the blank control group and negative control group, miR-212 inhibitor significantly inhibited cell proliferation (P＜0.05) and migration (P＜0.01) in MCF7 cells. Conclusion MiR-212 is high expressed in breast cancer, which may be involved in the development of breast carcinoma, indicating miR-212 might be a new target in breast cancer therapy. |
| Key words: microRNA miR-212 Breast cancer |
